^
Association details:
| Biomarker: | HR positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | capecitabine (Thymidylate synthase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
Excerpt:
A proposed treatment algorithm for the management of hormone receptor (HR)-positive, HER2-negative MBC...Recommendations...Beyond second line...Available drugs for single-agent ChT include anthracyclines, taxanes, capecitabine, eribulin, vinorelbine, platinums and other agents.
DOI:
https://doi.org/10.1016/j.annonc.2021.09.019.
Source:
Title:
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
Excerpt:
...- Participants with hormone-receptor positive tumors must have failed available lines of hormonal therapy unless hormone therapy was...
Trial ID:
Source:
Title:
Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer
Excerpt:
...- HR-positive & HER2-negative...
Trial ID:
More C2 evidence
Source:
Title:
A Multicenter, Randomized Clinical Trail Evaluate Effectiveness and Security of Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen After the 1st-line Chemotherapy With Capecitabine Combine Regimen in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer(Overstep)
Excerpt:
...- HR-positive & HER2-negative...
Trial ID:
Source:
Title:
A Phase 2 Study of Ruxolitinib With Capecitabine in Subjects With Advanced HER2-Negative Breast Cancer
Excerpt:
...7.Subjects with hormone-receptor positive tumors (ER+ and/or PR+) must have failed available appropriate lines of hormonal therapy, unless intolerant to hormonal therapy or hormonal therapy is not considered to be clinically appropriate. ...
Trial ID:
Source:
Title:
Reinduction with liposomal anthracyclines and Capecitabine in patients with breast cancer, locally advanced (IIIA-IIIB-IIIC) HER2 negative, not obtaining a pathological complete response (<PCR) after primary chemotherapy.
Excerpt:
...Patient with residual disease on breast and / or axillary lymph nodes (<PCR) after primary chemotherapy - Initial histologic diagnosis with pathological characterization of: Grading, RE / PGR, Ki67, p53 - Initial Stage IIIA, IIIB, IIIC - State hormone receptor positive or negative - State-negative HER2 achieved with immunohistochemical methods or in situ hybridization using fluorescence (FISH)...
Trial ID:
Less C2 evidence
Source:
Title:
Real-world clinical outcomes in patients (pts) with HR+/HER2- metastatic breast cancer (mBC) treated with chemotherapy (CT) in the United States (US).
Published date:
05/25/2023
Excerpt:
Pts (≥18 years) diagnosed with HR+/HER2- mBC….Capecitabine and paclitaxel were the most used as the first (45% and 29%), second (35% and 30%), and third (25% and 22%) CT, while gemcitabine (22%) and eribulin (20%) were used most as fourth CT....Median real-world overall survival (rwOS; 95% CI) from time of mBC diagnosis was 48.5 months (45.5-51.5). Median rwOS from first CT treatment start date was 23.3 months (21.3-25.4). In pretreated pts with 1, 2, or 3 prior lines of CT, median rwOS from each index date was 16.5 months (14.8-18.3), 11.8 months (10.4-13.1), and 9.1 months (7.3-11.2), respectively.
DOI:
10.1200/JCO.2023.41.16_suppl.e18871
Source:
Title:
239P - Efficacy of Single-Agent Chemotherapy in Endocrine Therapy-Refractory Metastatic Invasive Lobular Carcinoma
Published date:
05/07/2023
Excerpt:
We investigated the efficacy of capecitabine (CAP) versus taxanes (TAX) in ET-refractory HR+ HER2- mILC patients….Subjects who received CAP had statistically significant better median PFS compared to TAX (8.8 vs 5.0 months, HR 0.63, P <0.0001).
Source:
Title:
Capecitabine in Combination with Endocrine Therapy as Maintenance Therapy after Bevacizumab Plus Paclitaxel Induction Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: KBCSG-TR1214
Published date:
08/31/2021
Excerpt:
Patients who had received bevacizumab-paclitaxel induction therapy and did not have progressive disease (PD) were randomized to maintenance therapy with endocrine therapy alone (group E) or endocrine plus capecitabine (1657 mg/m2/day on days 1-21, q4w) (group EC). In case of PD after maintenance therapy, patients received bevacizumab-paclitaxel reinduction therapy. The median progression-free survival (PFS) under maintenance therapy (primary endpoint) was significantly longer in group EC (11.1 {95% CI, 8.0-11.8} months) than in group E (4.3 {3.6-6.0} months) (hazard ratio, 0.53; p < 0.01). At 24 months from the induction therapy start, the overall survival (OS) was significantly longer in group EC than in group E (hazard ratio, 0.41; p = 0.046). Addition of capecitabine to maintenance endocrine therapy may be a beneficial option after induction chemotherapy for HR-positive, HER2-negative AMBC patients.
DOI:
10.3390/cancers13174399
